SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Arcolab gains despite Goldman Sachs offloading 0.71% of its stake via open market route

11 Dec 2013 Evaluate

Strides Arcolab is currently trading at Rs 895.00, up by 18.05 points or 2.06 % from its previous closing of Rs 876.95 on the BSE.

The scrip opened at Rs. 899.70 and has touched a high and low of Rs. 910.00 and Rs. 890.10 respectively. So far, 316000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1200.00 on 21-Dec-2012 and a 52 week low of Rs. 552.65 on 01-Aug-2013.

Last one week high and low of the scrip stood at Rs 1050.00 and Rs 794.30 respectively. The current market cap of the company is Rs 5295 crore.

The promoters holding in the company stood at 27.36% while Institutions and Non-Institutions held 58.54% and 14.11% respectively.

Goldman Sachs Investments Mauritius has reportedly offloaded 4.20 lakh shares constituting 0.71% stake of Strides Arcolab through the open market route. The shares were sold on an average price of Rs 876.56 valuing the transaction to Rs 36.82 crore. 

Meanwhile, the company has declared a special dividend of Rs 500 per share in the wake of the $1.75-billion sale of its Agila Specialities Division to Mylan Inc of the US. The company returned 88% of the free cash available with it to the shareholders by way of special dividend.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

1121.50 -5.40 (-0.48%)
06-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1913.05
Dr. Reddys Labs. 1368.75
Cipla 1471.25
Zydus Lifesciences 1148.05
Lupin 2492.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: